{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:48:22Z","timestamp":1785404902170,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,8]]},"DOI":"10.7759\/cureus.91829","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:36:10Z","timestamp":1757334970000},"source":"Crossref","is-referenced-by-count":2,"title":["A New Era for Esketamine in Managing Treatment-Resistant Depression: A Systematic Review of Its Use From Adjunct to First-Line Therapy"],"prefix":"10.7759","author":[{"given":"Bhavya","family":".","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijan","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balakrishnan","family":"Sadasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/00048670802277206","article-title":"Treatment-resistant depression: critique of current approaches","volume":"42","author":"Wijeratne C","year":"2008","unstructured":"Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008, 42:751-62. 10.1080\/00048670802277206","journal-title":"Aust N Z J Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-977x(98)00004-2","article-title":"Treatment resistant depression: methodological overview and operational criteria","volume":"9","author":"Souery D","year":"1999","unstructured":"Souery D, Amsterdam J, de Montigny C, et al.. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999, 9:83-91. 10.1016\/s0924-977x(98)00004-2","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1223145","article-title":"Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression","volume":"17","author":"Lullau AP","year":"2023","unstructured":"Lullau AP, Haga EM, Ronold EH, Dwyer GE. Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression. Front Neurosci. 2023, 17:1223145. 10.3389\/fnins.2023.1223145","journal-title":"Front Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01381-x","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","volume":"27","author":"Sforzini L","year":"2022","unstructured":"Sforzini L, Worrell C, Kose M, et al.. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2022, 27:1286-99. 10.1038\/s41380-021-01381-x","journal-title":"Mol Psychiatry"},{"key":"ref5","unstructured":"Depressive disorder (depression). (2025). Accessed. April 5, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"ref6","unstructured":"Major depression. (2025). Accessed. April 5, 2025: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression."},{"key":"ref7","unstructured":"Updates from India. (2025). Accessed. April 5, 2025: https:\/\/www.who.int\/india\/news-room."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00205-y","article-title":"Treatment-resistant depression: molecular mechanisms and management","volume":"5","author":"Kajumba MM","year":"2024","unstructured":"Kajumba MM, Kakooza-Mwesige A, Nakasujja N, Koltai D, Canli T. Treatment-resistant depression: molecular mechanisms and management. Mol Biomed. 2024, 5:43. 10.1186\/s43556-024-00205-y","journal-title":"Mol Biomed"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852900015212","article-title":"Preventing relapse and recurrence of depression: a brief review of therapeutic options","volume":"11","author":"Thase ME","year":"2006","unstructured":"Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006, 11:12-21. 10.1017\/s1092852900015212","journal-title":"CNS Spectr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for the management of depression","volume":"59","author":"Gautam S","year":"2017","unstructured":"Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical practice guidelines for the management of depression. Indian J Psychiatry. 2017, 59:S34-50. 10.4103\/0019-5545.196973","journal-title":"Indian J Psychiatry"},{"key":"ref11","unstructured":"Clinical practice guideline for the treatment of depression across three age cohorts. (2025). Accessed. April 6, 2025: https:\/\/www.apa.org\/depression-guideline."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v68n0617","article-title":"Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials","volume":"68","author":"Crossley NA","year":"2007","unstructured":"Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007, 68:935-40. 10.4088\/jcp.v68n0617","journal-title":"J Clin Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai R","year":"2010","unstructured":"Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010, 67:26-36. 10.1001\/archgenpsychiatry.2009.175","journal-title":"Arch Gen Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance","volume":"66","author":"Shelton RC","year":"2005","unstructured":"Shelton RC, Williamson DJ, Corya SA, et al.. Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005, 66:1289-97. 10.4088\/jcp.v66n1012","journal-title":"J Clin Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/YCT.0000000000000840","article-title":"National network of depression centers\u2019 recommendations on harmonizing clinical documentation of electroconvulsive therapy","volume":"38","author":"Zandi PP","year":"2022","unstructured":"Zandi PP, Morreale M, Reti IM, et al.. National network of depression centers\u2019 recommendations on harmonizing clinical documentation of electroconvulsive therapy. J ECT. 2022, 38:159-64. 10.1097\/YCT.0000000000000840","journal-title":"J ECT"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20199","article-title":"Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial","volume":"14","author":"Levkovitz Y","year":"2015","unstructured":"Levkovitz Y, Isserles M, Padberg F, et al.. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015, 14:64-73. 10.1002\/wps.20199","journal-title":"World Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurom.2021.12.010","article-title":"Setting up a successful vagus nerve stimulation service for patients with difficult-to-treat depression","volume":"25","author":"Kraus C","year":"2022","unstructured":"Kraus C, Quach D, Sholtes DM, et al.. Setting up a successful vagus nerve stimulation service for patients with difficult-to-treat depression. Neuromodulation. 2022, 25:316-26. 10.1016\/j.neurom.2021.12.010","journal-title":"Neuromodulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava M","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, et al.. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020, 25:1592-603. 10.1038\/s41380-018-0256-5","journal-title":"Mol Psychiatry"},{"key":"ref19","article-title":"Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr R","year":"2019","unstructured":"Bahr R, Lopez A, Rey JA. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T. 2019, 44:340-75.","journal-title":"P T"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly EJ","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, et al.. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018, 75:139-48. 10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi Y","year":"2022","unstructured":"Alnefeesi Y, Chen-Li D, Krane E, et al.. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022, 151:693-709. 10.1016\/j.jpsychires.2022.04.037","journal-title":"J Psychiatr Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D(2\/3) receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto K","year":"2017","unstructured":"Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H. Reduction of dopamine D(2\/3) receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017, 267:173-6. 10.1007\/s00406-016-0692-7","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen MS","year":"2020","unstructured":"Salahudeen MS, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf. 2020, 11:2042098620937899. 10.1177\/2042098620937899","journal-title":"Ther Adv Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.53987","article-title":"Exploring esketamine\u2019s therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review","volume":"16","author":"Kumari S","year":"2024","unstructured":"Kumari S, Chaudhry HA, Sagot A, et al.. Exploring esketamine\u2019s therapeutic outcomes as an FDA-designated breakthrough for treatment-resistant depression and major depressive disorder with suicidal intent: a narrative review. Cureus. 2024, 16:e53987. 10.7759\/cureus.53987","journal-title":"Cureus"},{"key":"ref25","unstructured":"Janssen announces U.S. FDA approval of Spravatotm (esketamine) CIII nasal spray for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. (2019). Accessed. April 5, 2025: https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasa...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","volume":"182","author":"Fountoulakis KN","year":"2025","unstructured":"Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis. Am J Psychiatry. 2025, 182:259-75. 10.1176\/appi.ajp.20240515","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.03.137","article-title":"Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis","volume":"356","author":"Seshadri A","year":"2024","unstructured":"Seshadri A, Prokop LJ, Singh B. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis. J Affect Disord. 2024, 356:379-84. 10.1016\/j.jad.2024.03.137","journal-title":"J Affect Disord"},{"key":"ref28","unstructured":"FDA approves esketamine as first monotherapy for treatment-resistant depression. (2025). Accessed. April 4, 2025: https:\/\/www.hcplive.com\/view\/fda-approves-esketamine-first-monotherapy-treatment-resistant-depression."},{"key":"ref29","unstructured":"SPRAVATO\u00ae (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. (2025). Accessed. April 4, 2025: https:\/\/www.jnj.com\/media-center\/press-releases\/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monothe...."},{"key":"ref30","unstructured":"A study to evaluate the safety and efficacy of intranasal esketamine in treatment-resistant depression (SYNAPSE). (2025). Accessed. April 4, 2025: https:\/\/clinicaltrials.gov\/study\/NCT01998958."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404113-a-new-era-for-esketamine-in-managing-treatment-resistant-depression-a-systematic-review-of-its-use-from-adjunct-to-first-line-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:36:13Z","timestamp":1757334973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404113-a-new-era-for-esketamine-in-managing-treatment-resistant-depression-a-systematic-review-of-its-use-from-adjunct-to-first-line-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.91829","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}